Dados B3 › VIVR3 × RADL3
VIVR3 × RADL3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | VIVR3 | RADL3 | year |
|---|---|---|---|
| ROE | -34.9% | 18.9% | 2025 |
| ROIC | -10.0%! | 24.8% | 2025 |
| ROA | -7.2% | 5.5% | 2025 |
| Gross margin | 23.5% | 29.3% | 2025 |
| EBIT margin | -32.4% | 6.2% | 2025 |
| Net margin | -61.0% | 2.9% | 2025 |
| Net debt/EBITDA | 7.64x | -1.03x | 2010 |
| Current ratio | 0.90x | 1.46x | 2025 |
| Revenue growth (1y) | -74.5% | 13.8% | 2025 |
| Revenue growth (5y CAGR) | -8.1% | 17.1% | 2025 |
| Piotroski F-Score | 1/9 | 5/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | VIVR3 | RADL3 | year |
|---|---|---|---|
| P/E | -1.10x | 32.24x | 2025 |
| P/B | — | 5.71x | 2025 |
| EV/EBITDA | — | 9.37x | 2025 |
| FCF yield | -348.6% | 2.5% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-09 13:39 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.